HER2/Neu+ Uterine Serous Carcinoma
1 clinical trials · Condition
◉ Watch HER2/Neu+ Uterine Serous Carcinoma
| Record | Firm | Date |
|---|---|---|
| A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma (NCT02491099) | Yale University | 2015-06-01 |
Track HER2/Neu+ Uterine Serous Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.